Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza and Quviviq.
A complete database of all previous G-BA resolutions is available through my membership.
- Tezpire (tezepelumab); bronchial asthma, patients aged ≥ 12 years – For both subgroups, additional benefit not proven
- Adtralza (tralokinumab); new indication: atopic dermatitis, patients aged 12 to 17 years – Additional benefit not proven
- Quviviq (daridorexant); sleep disorders – Additional benefit not proven
- Hemgenix (etranacogen dezaparvovec); haemophilia B – Request for real-world data collection and restriction of prescribing
Follow me on Instagram to never miss the latest G-BA decisions (here 12 May 2023):